Schonfeld Strategic Advisors LLC Cyclacel Pharmaceuticals, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.75 $178,182 - $477,274	-636,366 Reduced 95.73%	28,400 $9,000
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.76 $37,055 - $54,158	-71,261 Reduced 9.68%	664,766 $392,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $19,248 - $39,528	-34,373 Reduced 4.46%	736,027 $419,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $21.75 $83,808 - $3.38 Million	155,200 Added 25.23%	770,400 $516,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $123,885 - $2.21 Million	100,720 Added 19.58%	615,200 $898,000
Q2 2022 Aug 15, 2022	SELL	$6.1 - $7.15 $1,830 - $2,145	-300 Reduced 0.06%	514,480 $556,000
Q1 2022 May 16, 2022	BUY	$5.93 - $7.6 $1.14 Million - $1.46 Million	192,407 Added 59.68%	514,780 $1.57 Million
Q4 2021 Feb 14, 2022	BUY	$6.04 - $8.03 $1.32 Million - $1.75 Million	218,448 Added 210.2%	322,373 $1.25 Million
Q3 2021 Nov 16, 2021	BUY	$8.02 - $11.0 $11,228 - $15,400	1,400 Added 1.37%	103,925 $548,000
Q2 2021 Aug 16, 2021	SELL	$7.59 - $10.48 $259,578 - $358,416	-34,200 Reduced 25.01%	102,525 $607,000
Q1 2021 May 17, 2021	BUY	$6.86 - $9.24 $937,933 - $1.26 Million	136,725 New	136,725 $972,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $4.51M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.